Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
Phase 2
396
about 6.5 years
18+
87 sites in AR, AZ, CA +24
About this study
This trial is testing whether mosunetuzumab and/or polatuzumab vedotin helps benefit patients who have received chemotherapy followed by chimeric antigen receptor (CAR) T-cell therapy for diffuse large B-cell lymphoma that has come back or does not respond to treatment. Mosunetuzumab and polatuzumab vedotin are given after CAR T-cell therapy may be more effective at controlling or shrinking the cancer than not giving them.
Based on ClinicalTrials.gov records.
What participants do
- 1.Patient Observation
- 2.Receive Axicabtagene Ciloleucel
- 3.Receive Lisocabtagene Maraleucel
- +3 more
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
axicabtagene ciloleucel, cyclophosphamide (Alkylating chemotherapy; crosslinks DNA strands), fludarabine, lisocabtagene maraleucel, mosunetuzumab, polatuzumab vedotin, tisagenlecleucel (CAR T-cell therapy targeting CD19 on leukemia cells)
infusion
Primary: Progression free survival (PFS)
Secondary: Association between total metabolic tumor volume (TMTV), standardized uptake value (SUV) max, and sum product (SPD) of diameters, Complete remission (CR) conversion rate, Conversion of CR, Incidence of adverse events, Overall survival (OS)
diagnostic, imaging
Oncology